OncoLog Volume 47, Number 04, April 2002

Researchers Focus on Bioimmunotherap for Treatment of Non-Hodgkin\u27s Lymphomas Protocols: Non-Hodgkin\u27s Lymphoma Studies House Call: The First Cancer Prevention Vaccine DiaLog: The Viral Origins of Lymphomas, by Felipe Samaniego, MD, Assistant Professor, Department of Lymphoma and Myeloma Research Consortium Recruiting Volunteers to Study the Role of Genetics in Cancer Development and Patient Carehttps://openworks.mdanderson.org/oncolog/1105/thumbnail.jp

LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2

Additional file 4: Figure S3. Representative images of colony formation of Mino cells. a The number of colonies in MALAT1 knockdown Mino cells were significantly reduced. b Photographs of colonies in colony formation assay. The size of individual colony was significantly reduced in MALAT1 knockdown Mino cells

Mejora del acceso al financiamiento bancario de empresas MYPES, usando herramientas de Data Mining

El presente trabajo tiene como objetivo dar a conocer una metodología simple para optimizar el acceso al financiamiento bancario para una MYPE a través del uso de herramientas de minería de datos que puedan plasmarse en un aplicativo móvil con una interface amigable para el usuario, que en este caso podría ser el gerente general, el gerente financiero, entre otros; sin demandar una inversión muy alta. La herramienta de minería de datos que se aplicó fue una red neuronal con aprendizaje profundo, pues involucra más de una capa oculta – mayor cantidad de capas, mayor precisión – para a partir de variables disponibles en un set de datos, determinar el peso relativo de cada una de ellas y estimar la probabilidad de que una MYPE en particular pueda acceder a un crédito bancario. Se aplicó también otra herramienta conocida como regresión logística, sin embargo, por el potencial de aplicación del algoritmo anterior, se descartó la última opción. En ambos casos se usó un dataset de un banco representativo de nuestro país, con historial de créditos aprobados o denegados para MYPEs de diferentes segmentos. La practicidad del resultado del algoritmo de minería de datos permite que pueda convertirse fácilmente en un app para móviles que, a través de una simple interface de usuario, le permite a una MYPE conocer la probabilidad de acceso al financiamiento de forma personalizada. Esta información es de mucha utilidad para facilitar la toma de decisiones a nivel gerencial y a nivel estratégico (negociar con nuevos proveedores, con clientes, etc.) Se estimó un beneficio estimado anual de S/1683 por el uso de este aplicativo respecto a no utilizarlo, en un escenario normal proyectado para 5 años en adelante. De la misma forma, se tuvo un VAN de S/3368 para un COK de 14.71%. Asimismo, para un WACC de 20.95% producto de una estructura de financiamiento 20% deuda y 80% aporte propio, el VAN calculado es de S/2360. En ambos escenarios el proyecto de implementación resulta económicamente viable. Sintetizando, se tendrá un aplicativo móvil desarrollado a partir del algoritmo de minería de datos –redes neuronales– que permitirá a la MYPE tomar decisiones más acertadas.Tesi

Construcción de marca en el marketing político el caso de Barack Obama

Este trabajo de grado es una primera aproximación a un tema novedoso como lo es el Marketing Político. Marketing ha sido un campo que ha cobrado vigencia sobre todo cuando las empresas han tenido problemas para conseguir clientes y vender sus productos y/o servicios. Esta situación se traslada al campo de la política, en el cual se lucha por conseguir el mayor número de votos, haciendo que en este contexto llegue el Marketing político como un instrumento clave para ganar electores en las campañas políticas.This degree work is a first approach to a new subject like Political Marketing. Marketing has been a field that has become force especially when companies had trouble getting customers and sell their products and / or services. This moves to the politics fields, where it seeks to achieve the highest number of votes, so that in this context comes the political marketing as a key tool to win voters in political campaigns.Administrador (a) de EmpresasPregrad

Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis

Objectives: The current study aimed to assess the impact of HIV on the production of anti-HCV antibodies in HCV-infected individuals with advanced HCV-related cirrhosis before and 36 weeks after the sustained virological response (SVR) induced by direct-acting antivirals (DAAs) therapy. Methods: Prospective study on 62 patients (50 HIV/HCV-coinfected and 12 HCV-monoinfected). Plasma anti-E2 and HCV-nAbs were determined respectively by ELISA and microneutralization assays. Results: At baseline, the HCV-group had higher anti-E2 levels against Gt1a (p = 0.012), Gt1b (p = 0.023), and Gt4a (p = 0.005) than the HIV/HCV-group. After SVR, anti-E2 titers against Gt1a (p < 0.001), Gt1b (p = 0.001), and Gt4a (p = 0.042) were also higher in the HCV-group than HIV/HCV-group. At 36 weeks post-SVR, plasma anti-E2 titers decreased between 1.3 and 1.9-fold in the HIV/HCV-group (p < 0.001) and between 1.5 and 1.8-fold in the HCV-group (p ≤ 0.001). At baseline, the HCV-group had higher titers of HCV-nAbs against Gt1a (p = 0.022), Gt1b (p = 0.002), Gt2a (p < 0.001), and Gt4a (p < 0.001) than the HIV/HCV-group. After SVR, HCV-nAbs titers against Gt1a (p = 0.014), Gt1b (p < 0.001), Gt2a (p = 0.002), and Gt4a (p = 0.004) were also higher in the HCV-group. At 36 weeks post-SVR, HCV-nAbs decreased between 2.6 and 4.1-fold in the HIV/HCV-group (p < 0.001) and between 1.9 and 4.0-fold in the HCV-group (p ≤ 0.001). Conclusions: HIV/HCV-coinfected patients produced lower levels of broad-spectrum anti-HCV antibodies than HCV-monoinfected patients.This study was supported by grants from Instituto de Salud Carlos III (ISCII; grant numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI19CIII/00009 to IM, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the Spanish AIDS Research Network (RD16/0025/0017, RD16/0025/0018 and RD16CIII/0002/0002) and CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU (CB21/13/00044 and CB21/13/00039). DSC is a ‘Sara Borrell’ researcher from ISCIII (grant number CD20CIII/00001).S

Corioamnionitis más tuberculosis peritoneal en paciente embarazada de 21 semanas de gestación. Reporte de caso

Chorioamnionitis is acute inflammation of the amnion and chorion, it is a marker of intra-amniotic infection, although it can occur in the absence of detectable infection. Histologic chorioamnionitis, identified through pathologic examination of the placenta, may be present in the absence of clinical chorioamnionitis, which is diagnosed primarily by maternal fever. Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis, which constitutes a public health problem in the world. Peritoneal tuberculosis (TBP) is a low-incidence pathology that represents 0.34% of tuberculosis cases. Its clinical presentation is usually nonspecific and insidious. A case of a 21-week pregnant patient is reported by date of last menstruation who comes due to a temperature rise greater than 38 degrees Celsius, accompanied by abdominal pain type uterine contractions 1 out of 10 that last approximately 5 seconds. Patient is admitted to the gynecology and obstetrics areaLa corioamnionitis es la inflamación aguda del amnios y el corion, es un marcador de infección intraamniótica, aunque puede ocurrir en ausencia de infección detectable. La corioamnionitis histológica, identificada a través del examen patológico de la placenta, puede estar presente en ausencia de corioamnionitis clínica, que se diagnostica principalmente por fiebre materna. La tuberculosis es una enfermedad infecciosa causada por la bacteria Mycobacterium tuberculosis, que constituye un problema de salud pública en el mundo. La tuberculosis peritoneal (TBP) es una patología de baja incidencia que representa el 0.34% de los casos de tuberculosis. Su presentación clínica suele ser inespecífica e insidiosa. Se Reporta un caso de un paciente gestante de 21 semanas por fecha de ultima menstruación que acude por presentar alza térmica mayores a 38 grados centígrados, acompañada de dolor abdominal tipo contracciones uterinas 1 de 10 que duran aproximadamente 5 segundos. Paciente es ingresada al área de ginecología y obstetricia

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

PURPOSE: Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL, particularly in the non-germinal center B-cell-like subset. METHODS: We enrolled 60 patients with newly diagnosed non-germinal center B-cell-like DLBCL in this investigator-initiated, single-arm phase II trial of rituximab, lenalidomide, and ibrutinib (RLI) with the sequential addition of chemotherapy (ClinicalTrials.gov identifier: NCT02636322). Patients were treated with rituximab 375 mg/m RESULTS: The median age was 63.5 years (range, 29-83 years) with 28% age 70 years or older. The revised international prognostic index identified 42% as high risk, and 62% were double expressor of MYC and BCL2 protein. The ORR after two cycles of RLI was 86.2%, and the complete response rate at the end of RLI-chemotherapy was 94.5%. With a median follow-up of 31 months, the progression-free survival and overall survival were at 91.3% and 96.6% at 2 years, respectively. CONCLUSION: Smart Start is the first study, to our knowledge, to treat newly diagnosed DLBCL with a targeted therapy combination before chemotherapy. RLI produced a high ORR, and RLI with chemotherapy resulted in durable responses. This establishes the potential for developing biologically driven and noncytotoxic first-line therapies for DLBCL

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not been explored. We performed a retrospective analysis of 346 patients with advanced stage follicular lymphoma (FL) without histological evidence of transformation, and analyzed the impact of SUVmax on outcome after frontline therapy. Fifty-two (15%) patients had a SUVmax >18, and a large lymph node ≥6 cm was the only factor associating with SUVmax >18 on multivariate analysis (odds ratio 2.7, 95% confidence interval [CI]: 1.3-5.3, P=0.006). The complete response rate was significantly lower among patients treated with non-anthracycline-based regimens if SUVmax was >18 (45% vs. 92%, P18 was associated with significantly shorter progression-free survival among patients treated with non-anthracycline-based regimens (77 months vs. not reached, P=0.02), but not among patients treated with R-CHOP (P=0.73). SUVmax >18 associated with shorter overall survival (OS) both in patients treated with R-CHOP (8-year OS 70% vs. 90%, P=0.02) and non-anthracycline-based frontline regimens (8-year OS 50% vs. 85%, P=0.001). In conclusion, pre-treatment PET scan has prognostic and predictive value in patients with advanced stage FL receiving frontline treatment

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London